

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[Docket No. 6-98]

Foreign-Trade Zone 37—Orange County, New York, Area, Application for Expansion; Extension of Public Comment Period

The comment period for the above case, submitted by the County of Orange, New York, requesting authority to expand its zone in the Orange County, New York, area (63 FR 6890, 2/11/98), is extended to May 13, 1998, to allow interested parties additional time in which to comment on the proposal.

Comments in writing are invited during this period. Submissions should include three (3) copies. Material submitted will be available at: Office of the Executive Secretary, Foreign-Trade Zones Board, U.S. Department of Commerce, Room 3716, 14th & Pennsylvania Avenue, NW, Washington, DC 20230.

Dated: April 8, 1998.

Dennis Puccinelli,

Acting Executive Secretary.

[FR Doc. 98-10414 Filed 4-20-98; 8:45 am]

BILLING CODE 3510-DS-P

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[Docket 20-98]

Foreign-Trade Zone 61—San Juan, Puerto Rico, Application for Subzone, Pfizer Pharmaceuticals, Inc. (Pharmaceutical Products), Barceloneta, Puerto Rico

An application has been submitted to the Foreign-Trade Zones Board (the Board) by the Commercial and Farm Credit and Development Corporation of Puerto Rico, grantee of FTZ 61, requesting special-purpose subzone status for the pharmaceutical manufacturing plant of Pfizer Pharmaceuticals, Inc. (Pfizer), in Barceloneta, Puerto Rico. The application was submitted pursuant to the provisions of the Foreign-Trade Zones Act, as amended (19 U.S.C. 81a-81u), and the regulations of the Board (15 CFR part 400). It was formally filed on April 13, 1998.

Pfizer is a wholly-owned subsidiary of Pfizer Inc. (U.S.), which comprises three global businesses—Health Care,

Consumer Health Care and Animal Health.

Pfizer's Barceloneta plant (420,000 sq. ft. on 95 acres + 150-acre adjacent area) is located at Road 2, KM 58.2, Barceloneta, Puerto Rico, some 45 miles west of San Juan. The facility (with some 1,000 employees) produces finished pharmaceutical products, primarily SINEQUAN®, DIABINESE®, ANTIVERT®, MINIPRESS®, FELDEN®, GLUCOTROL®, PROCARDIA XL®, NORVASC®, CARDURA®, DIFLUCAN®, ZOLOFT®, and ZITHROMAX®.

The company may locate production of three new products, VIAGRA® treatment for erectile dysfunction (HTSUS 3004.90.9040), TIKOSYN® anti-arrhythmia treatment (HTSUS 3004.90.9020) and eletripten migraine treatment (HTSUS 3004.90.9040) at the Barceloneta facility contingent upon receiving approval for subzone procedures at the plant. Foreign-sourced materials will account for, on average, 86 percent of materials value, and include items from the following categories:

Aromatic ethers and their derivatives

HTSUS 2909.30.4000 10.3%

Aromatic monoamines and their derivatives, salts

HTSUS 2921.49.4500 10.7%

Organo-sulfur compounds

HTSUS 2930.90.9050 3.7%

Heterocyclic compounds with nitrogen hetero-atoms(s):

HTSUS 2933.19.9000 6.8%

HTSUS 2933.59.5300 6.6%

HTSUS 2933.59.7000 10.7%

HTSUS 2933.90.7900 10.7%

HTSUS 2933.90.9000 3.7%

The company may also purchase from abroad other ingredients and materials in the following general categories:

gums, starches, waxes, vegetable extracts, mineral oils, sugars, empty capsules, protein concentrates, prepared animal feed, mineral products, inorganic acids, chlorides, chlorates, sulfites, sulfates, phosphates, cyanides, silicates, radioactive chemicals, rare-earth metal compounds, hydroxides, hydrazine and hydroxylamine, chlorides, phosphates, carbonates, hydrocarbons, alcohols, phenols, ethers, epoxides, acetals, aldehydes, ketone function compounds, mono- and polycarboxylic acids, phosphoric esters, amine-, carboxymide, nitrile- and oxygen-function compounds, heterocyclic compounds, sulfonamides, insecticides, rodenticides, fungicides and herbicides, fertilizers, vitamins,

hormones, antibiotics, gelatins, enzymes, pharmaceutical glaze, essential oils, albumins, gelatins, activated carbon, residual lyes, acrylic polymers, color lakes, soaps and detergents, various packaging and printing materials, medicaments, pharmaceutical products, and instruments and appliances used in medical sciences. Some 10 percent of production may be exported.

Zone procedures would exempt Pfizer from Customs duty payments on foreign materials used in production for export. On domestic sales, the company would be able to choose the duty rates that apply to the finished products (duty-free). The duty rates on foreign-sourced items range from duty-free to 18.6 percent. At the outset, zone savings would primarily involve choosing the finished product duty rate on VIAGRA®, TIKOSYN® and eletripten (duty-free), rather than the rates for their foreign components listed above (duty rates ranging from 3.7% to 10.7%). The application indicates that the savings from zone procedures will help improve the plant's international competitiveness.

In accordance with the Board's regulations, a member of the FTZ Staff has been designated examiner to investigate the application and report to the Board.

Public comment is invited from interested parties. Submissions (original and 3 copies) shall be addressed to the Board's Executive Secretary at the address below. The closing period for their receipt is June 22, 1998. Rebuttal comments in response to material submitted during the foregoing period may be submitted during the subsequent 15-day period (to July 6, 1998).

A copy of the application and accompanying exhibits will be available for public inspection at each of the following locations:

U.S. Department of Commerce Export Assistance Center, Plaza Torre, 525 F.D. Roosevelt Ave., Suite 905, San Juan (Hato Rey), Puerto Rico 00918

Office of the Executive Secretary, Foreign-Trade Zones Board, U.S. Department of Commerce, Room 3716, 14th and Pennsylvania Avenue, NW., Washington, DC 20230

Dated: April 14, 1998.

Dennis Puccinelli,

Acting Executive Secretary.

[FR Doc. 98-10572 Filed 4-20-98; 8:45 am]

BILLING CODE 3510-DS-P